Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase

NCT00991146 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

19

Enrollment

INDUSTRY

Sponsor class

Conditions

Cryopyrin-associated Periodic Syndromes
Familial Cold Autoinflammatory Syndrome
Muckle-Wells Syndrome
Neonatal Onset Multisystem Inflammatory Disease

Interventions

DRUG: canakinumab

Sponsor

Novartis Pharmaceuticals